Irregular sleeping pattern increases the risk of type 2 diabetes
Type 2 diabetes (T2D) is a chronic disorder that results from the body’s inability to make use of available insulin…
Type 2 diabetes (T2D) is a chronic disorder that results from the body’s inability to make use of available insulin…
Chinese pharmaceutical company Gan & Lee Pharmaceuticals has released Phase IIb data for its glucagon-like peptide 1 (GLP-1) receptor agonist…
Innovent Biologics has announced positive results from the Phase III DREAMS-1 clinical trial of mazdutide (IBI362), meeting the primary and…
US-based Know Labs has reported positive data from a proof-of-concept trial evaluating its device that non-invasively identifies the level of…
Vivani Medical has announced plans to start the first clinical study of its investigational six-month glucagon-like peptide 1 (GLP-1) implant…
Biophytis has obtained investigational new drug (IND) approval from the US Food and Drug Administration (FDA) to initiate its Phase…
Pfizer has selected a preferred once-daily modified-release formulation for its weight loss candidate danuglipron, as the company looks to get…
According to GlobalData’s Clinical Trials database, AI-related pharmaceutical research in clinical trials predominantly occurs in areas such as oncology and…
Zhejiang Doer Biologics (Doer Bio) has concluded subject enrolment in a Phase Ib/IIa clinical trial of DR10624 in obese patients with…
Boehringer Ingelheim and Gubra have initiated a Phase I clinical trial of BI 3034701, a long-acting triple agonist peptide designed to…